Noliprel biini ntuziaka maka ojiji

• Mlọ ọgwụ
• Ihe ngosi maka ojiji
• Ofzọ nke ngwa
• Nsonaazụ
• Ihe ngbanwe
• Ime
• Mmekọrịta na ọgwụ ndị ọzọ
• Dodoụbiga ya ókè
• Ọnọdụ nchekwa
• Mpempe mwepụta
• Ngwakọta

Noliprel Bi-forte bụ ngwakọta nke ACE inhibitor perindopril arginine na ebepamide sulfonamide diuretic. Mmetụta ọgwụ na-akpata ọgwụ bụ n'ihi njirimara nke akụrụngwa ọ bụla (perindopril na ebepamide) na synergism ha na-agbakwunye.
Perindopril bụ ihe mgbochi ACE. ACE na-atụgharị angiotensin nke m n'ime angiotensin II (ihe vasoconstrictor), na-akpali ihe nzuzo nke aldosterone site na eriri akpa adrenal na ndakpọ nke bradykinin (ihe na-akpata vasodilating) na heptapeptides na-adịghị arụ ọrụ.
Indapam bụ usoro nke sulfonamides nwere mgbanaka indole, nke ọgwụ metụtara thiazide diuretics, na-eme ihe site na igbochi sodium reabsorption na akụkụ cortical nke akụrụ. Nke a na - eme ka mmịpụta sodium na chlorides dị na mmamịrị na, ruo obere ala, potassium na magnesium, si otú a na-abawanye urination ma na-enye mmetụta antihypertensive.
Characterization nke antihypertensive edinam.
Noliprel Bi-forte na-ebelata ọbara mgbali systolic na diastolic na ndị ọrịa nwere ọbara mgbali elu nke afọ ọ bụla, ma na ọkwa supine na ọnọdụ kwụ ọtọ. Mmetụta antihypertensive nke ọgwụ bụ ịdabere na dose.
E mepụtara ụzọ kachasị mma iji belata akara aka ekpe ventricular uka na 8 mg perindopril (nke ruru 10 mg perindopril arginine) + 2.5 mg ebepamide.
Ọbara ọbara belatara nke ọma karị na ìgwè perindopril / ebepamide: ọdịiche pụtara mbelata BP n'etiti otu abụọ nke ndị ọrịa bụ –5.8 mm Hg maka nrụgide systolic. Art. (95% CI (–7.9, –3.7), p 15 mg / L (> 135 μmol / L) n'ime ụmụ nwoke na> 12 mg / L (> 110 μmol / L) na ụmụ nwanyị.
Iodine nwere ihe di iche di iche. N'ihe banyere akpịrị ịkpọ nkụ na-eji iji ọgwụ akpọnwụ akpọnwụ akpọnwụ, ihe ize ndụ nke ịmalite ịrịa oke gbasara akụrụ na-abawanye, ọkachasị mgbe ị na-eji ndị na ayodiin nwere ọgwụ dịgasị iche. Okwesiri ime ka nguzobe mmiri di na tupu nhọpụta ayodiin nwere ihe dị iche iche nwere.
Ngwakọta ọka nnu. Hypercalcemia nwere ike ime n'ihi mbelata urinary calcium excretion.
Cyclosporin. Ọ ga - ekwe omume ịbawanye ọkwa creatinine na plasma ọbara na-enweghị emetụta ogo cyclosporin na - ekesa, ọbụlagodi na enweghị mmiri na ụkọ sodium.

Dodoụbiga ya ókè

N'ihe banyere ịdoụbiga mmanya ókè, mmeghachi omume akachasị njọ bụ hypotension arterial, nke nwere ike ibute ya oge ụfọdụ site na ọgbụgbọ, ọgbụgbọ, ọgbụgbọ, ọgbụgbọ, ụra, ọgba aghara, ọrịrị Mmebi nke mmiri-electrolyte nguzozi (mbelata ogo nke potassium na sodium na plasma ọbara), ọdịda akụrụ, hyperventilation, tachycardia, palpitations obi (palpitation), bradycardia, nchegbu, na ụkwara nwere ike ịdapụta.
Enyemaka mbu gụnyere iwepu ọgwụ ngwa ngwa n'ahụ ahụ: mkpochi afọ na / ma ọ bụ ịhọpụta unyi na-arụ ọrụ, emesia ịhazigharị mmiri mmiri ọgwụ.
N'ọnọdụ dị mkpa hypotension, a ga-enyerịrị onye ọrịa ahụ ọnọdụ kwụ ọtọ yana okpokoro isi dị ala. Ọ bụrụ na ọ dị mkpa, ekwesịrị iji ọgwụgwọ mkpụrụ ndụ isotonic sodium chloride ma ọ bụ tinye usoro ọ bụla iji weghachi olu ọbara.
Perindoprilat, ụdị arụ ọrụ nke perindopril, nwere ike wepụrụ ya n'ahụ site na hemodialysis (lee Pharmacokinetics).

Kedu ihe ndị na-azụ ahịa kwesịrị ịma gbasara ọgwụ a?

Ngwakọta nke mbadamba nkume ndị dị ka ihe ndozi gụnyere lactose monohydrate. A na-ejikarị ihe a eme ihe maka imepụta ọgwụ dị iche iche.

N'agbanyeghị akụrụngwa anụ ahụ na kemịkalụ bara uru, lactose bụ ihe ahu kachasị sie ike. Maka ndị mmadụ na-ata ahụhụ na nnabata nke shuga mmiri ara, ntuziaka maka iji gbochie ị .ụ ọgwụ.

Na mgbakwunye, ndị ọrịa na-agbaso nri siri ike nke na-enweghị nnu, a ga-eji ọgwụ kpachapụrụ anya. Illsnweta ọgwụ nwere ike iduga n'ọbara ọbara ngwa ngwa. Agbanyeghị, ọ bụrụ na nke a mere mgbe etinyere ngwa nke mbụ ahụ, ihe kpatara ya nwere ike ịbụ usoro ọgwụgwọ adịghị mma.

A na-arụ ọrụ dị mkpa site na ịnweta mmiri zuru oke. Ikwesighi iwelie ọnụ mmiri mmiri, mana na ihu igwe ọkụ, ọ ka mma ị percentụ pasenti 25 karịa ka ọ dị na mbụ. Ọsụsọ mụbara yana ị canụ ọgwụ nwere ike bute mmiri akpịrị.

Nsonaazụ

Ọbụna ọgwụ ọgwụ onye ọkachamara gwara ka ọ rụọ nwere ike ibute nsonaazụ na-adịghị mma na ụfọdụ ndị. Noliprel A Be Forte, nyocha nke na-akwado ozi a, nwekwara ike ibute nsonaazụ.

Tebụl 3. Nsonaazụ ndị enwere ike

Sistemụ akwara Central	Iwe iwe, nchekasị, nsogbu ihi ụra, wdg.
Usoro mkpụrụ ndụ	Diureis mụbara, libido belatara, ịda mba, wdg.
Mmeghachi omume nfụkasị ahụ	Anaphylactic ujo, urticaria, eczema, angioedema, wdg.
Akụkụ akụkụ akụkụ akụkụ iku ume	Afia, akpukpo ahihia, rhinitis na ndi ozo.
Ọkpụkpụ afọ	Nausea, vomiting, afọ ọsịsa, ịba ọcha n'anya ọgwụ, wdg.
Akụkụ anụ ahụ	Tinnitus na-ebuwanye ibu, uto nke metal, na ndị ọzọ.
Ndị ọzọ	Ọsụsọ na-agba oke.

Nsonaazụ ndị ọzọ nwere ike ịdị iche na ndị edepụtara na tebụl. Enwere ike ịchọta ndepụta zuru ezu na ntuziaka maka ojiji.

Mgbe nyochachara Dr. Noliprel AB Forte, ntụnyere nke dị mfe ịzụta na ụlọ ahịa ọgwụ ọ bụla, ị nwere ike dochie ya:

• Indapamide + Perindopril,
• Ko-Perineva,
• Noliprel (A, A Bi, A Forte), wdg.

Analogs Noliprel Be Forte na-enwekarị otu ihe / na-arụ otu. Agbanyeghị, usoro onunu ogwu na onu ahia gi nwere ike di iche iche.

Enwere ike ịchọta ozi bara uru banyere ihe kpatara ọbara mgbali elu na vidiyo na-esonụ:

Mwepụta wepụtara ya na ihe mejupụtara

A na-ewepụta ọgwụ n'ụdị mbadamba ihe eji eme ihe nkiri: biconvex, okirikiri, ọcha (29 ma ọ bụ 30 nke ọ bụla n'ime karama polypropylene nke nwere akwa na pịnye nwere jel na-amị mmiri, karama 1 n'ime igbe kaadi nwere ikike nchịkwa mbụ, maka ụlọ ọgwụ - Pcs 30. n'ime karama polypropylene nwere onye na-enye ihe, karama 3 n’ime igbe kaadiboodu nke nwere ikike izizi, karama iri n’ime igbe kaadiboodu, n’ime igbe kaadiodu nke nwere ikike izizi 1 pallet na ntuziaka maka iji Noliprel A Bi-f ọnụ).

Ngwakọta 1 mbadamba:

• bekee na-arụ ọrụ: perindopril arginine - 10 mg (nke kwekọrọ na perindopril na ego nke 6.79 mg), ebepamide - 2.5 mg,
• ihe ndị ọzọ: anhydrous colloidal silicon dioxide, magnesium stearate, lactose monohydrate, maltodextrin, sodium carboxymethyl stachi (ụdị A),
• mkpuchi ihe nkiri: magnesium stearate, macrogol 6000, titanium dioxide (E171), hypromellose, glycerol.

Omume ọgwụ

NOLIPREL BI-FORTE bụ ngwakọta nke ihe abụọ na - arụ ọrụ, perindopril na ebepamide. Nke a bụ ọgwụ hypotensive, a na-eji ya agwọ ọbara mgbali elu (ọbara mgbali elu). NOLIPREL BI-FORTE ka edepụtara maka ndị ọrịa ewerelarịrị perindopril 0 mg na ebepamide 2.5 mg iche. Kama, ndị ọrịa dị otu a nwere ike were otu mbadamba NOLIPREL BI-FORTE, nke nwere ihe abụọ a.

Ihe ngosi maka ojiji

Perindopril so na otu ọgwụ a na-akpọ ACE inhibitors. Ọ na - eme ya site na itinye ike na - agbasawanye n'ahụ akwara ọbara, nke na - eme ka ọbara gbasaa. Indapamide bụ ọrịa diuretic. Diuretics na-abawanye oke mmamịrị nke akụrụ na-emepụta. Agbanyeghị, ebepamide dị iche na ọgwụ ndị ọzọ, n'ihi na ọ na-eme ka mmamịrị na -ewelite obere ume. Ihe ọ bụla n’ime ọrụ ndị na-arụ ọrụ na-ebelata ọbara mgbali elu ma ha abụọ na-ejikwa ọbara mgbali elu.

Ihe ngbanwe

- oburu na i nwere ihe nfụkasị perindopril, ihe ndi ozo ACE inhibitor, ebepamide, otu n’ime sulfonylamides ma obu ihe ndi ozo nke NOLIPREL BI-FORT,

- ọ bụrụ na mbụ, mgbe ị na - ewere ndị ọzọ na - egbochi ACE ma ọ bụ n'ọnọdụ ndị ọzọ, gị ma ọ bụ otu onye n'ime ndị ezinụlọ gị gosipụtara ihe mgbaàmà dịka ọrịrị, ọsịsọ nke ihu ma ọ bụ ire, oke ahụ mgbu, ma ọ bụ ihe nchapu nke anụ ahụ (angiotherapy).

- ma ọ bụrụ na ị nwere ọrịa ọrịa imeju ma ọ bụ encephalopathy hepatic (ọrịa ụbụrụ na-emebi emebi),

- ọ bụrụ na ị na-arụ ọrụ na-arụ ọrụ nke ukwuu ma ọ bụ ọ bụrụ na ị na-enwe usoro ọgwụgwọ,

- ọ bụrụ na ọkwa ọbara nke ọbara ọbara gị dị ala ma ọ bụ nke ukwuu,

- ọ bụrụ n ’ị na-enyo enwetaghị ọgwụ aghara, akụrụngwa nke enweghị ike (njigide nnu dị ukwuu, mkpụmkpụ ume)

- Ọ bụrụ na ị dị ime, afọ ime ahụ gafere ọnwa 3 (ọ ka mma izere iwere ya. NOLIPRELA B-FORT na mmalite nke afọ ime - lee “Oge ime na inye nwa”),

- ma ọ bụrụ na ị na-enye nwa ara.

Gwa dọkịta gị tupu ị were NOLIPREL BI-FORTE ma ọ bụrụ na ihe ndị a:

ma ọ bụrụ na ị na-arịa ụtarị ụrọ (ọ na - emechi akwara ọbara nke na - esite n’obi), hypertrophic cardiomyopathy (obi akwara obi), ma ọ bụ akụrụ gbasara akwara (ọnya na - ebunye ọbara akụrụ), ọ bụrụ na inata ọrịa obi ọzọ, ọ bụrụ na ị na - arịa ọrịa imeju.

ọ bụrụ na ị na-arịa ọrịa vaskụla collagen (ọrịa akpụkpọ) dịka systemic lupus erythematosus ma ọ bụ scleroderma,

ọ bụrụ na ị na-arịa ọrịa atherosclerosis (isi ike nke akwara akwara),

ọ bụrụ na ị na-arịa hyperparathyroidism (ịba ụba ọrụ parathyroid),

ọ bụrụ na ị na-ata ahụhụ si gout,

ọ bụrụ na ị nwere ọrịa shuga

ọ bụrụ na ị na-eri nri nnu dị obere ma ọ bụ na-ewere ọgwụ nnu ndị nwere potassium,

ọ bụrụ na ị na-a litụ ọgwụ lithium ma ọ bụ potassium-sparing diuretics (spironolactone, triamteren), dịka ịgaghị ewere ha n'otu oge ahụ NOLIPREL BI-FORT (lee “drugsakingụ ọgwụ ọjọọ”).

Kwesịrị ịgwa dọkịta gị ma ọ bụrụ na ị chere na ị dị ime. (ma ọ bụ na-eme atụmatụime). Achọghị ka ọ were NOLIPREL BI-FORT n'oge mmalite nke afọ ime. Ekwesighi ị Theụ ọgwụ ahụ ogologo oge karịa ọnwa 3, n'ihi na nke a nwere ike imerụ ahụike nwatakịrị ahụ (lee “Oge ime na lactation”).

Mgbe ị na-ewere NOLIPREL BI-FORT, ị ga-agwa dọkịta gị ma ọ bụ ndị ọrụ ahụike gbasara ihe ndị a:

ọ bụrụ na ị nwere mọtikoiki ma ọ bụ ịwa ahụ ukwu,

ọ bụrụ na ị nwere ọrịa shuga ma ọ bụ na-agbọ agbọ n’oge na-adịbeghị anya, ma ọ bụ ọ bụrụ na akpịrị gị na-asọ.

oburu na inwere oria nke LDL (ewepu cholesterol na obara).

ọ bụrụ na ị nwere nkụda mmụọ, nke kwesịrị belata mmeghachi ahụ nfụkasị bee ma ọ bụ ihe mkpofu,

ọ bụrụ na ị na-ele nyocha ahụike chọrọ njikwa nke radioineine nke nwere iodine nwere (ihe na-eme ka o kwe omume inyocha akwara dị n’ime, dịka akụrụ ma ọ bụ afọ, na iji x-ụzarị).

Ndị na-eme egwuregwu kwesịrị ịmara na NOLIPREL BI-FORTE nwere ihe na-arụ ọrụ (ebepamide), nke nwere ike inye mmeghachi omume dị mma mgbe ị na-eduzi njikwa doping.

NOLIPREL BI-FORT ekwesighi inye umuaka umuaka.

Ime na lactation

Gwa dọkịta gị ma ọ bụ onye na-ere ọgwụ tupu ị medicationụọ ọgwụ ọ bụla.

You ga-adọ dọkịta gị aka na ntị ma ọ bụrụ na iche na ị dị ime (ma ọ bụ ime atụmatụime).

Dọkịta gị kwesịrị ịgwa gị ka ị kwụsị ị Nụ NOLIPREL BI-FORTE tupu ịtụrụ ime ma ọ bụ ozugbo ekwesịrị ịkọwapụta afọ ime, ma depụta ọgwụ ọzọ kama NOLIPREL BI-FORT. Achọghị ka ọ were NOLIPREL BI-FORT n'oge mmalite nke afọ ime. Ekwesighi ị drugụ ọgwụ ahụ ogologo oge karịa ọnwa 3, n'ihi na nke a nwere ike imerụ ahụike nke nwatakịrị ahụ.

Ọ bụrụ n’ị na-enye nwa ara ma ọ bụ na-eme atụmatụ ị breastụ ara, gwa dọkịta gị. NOLIPREL BI-FORTE na-contraindicated na nne ara. Dọkịta gị nwere ike inye gị ọgwụgwọ ọzọ ma ọ bụrụ na ịchọrọ ị breastụ ara, ọkachasị ma ọ bụrụ na nwa amụrụ ọhụrụ ma ọ bụ mụọ tupu oge ọmụmụ ya.

Gwa dọkịta gị ozugbo.

Usoro onunu ogwu na nhazi

Mgbe ị na-ewere NOLIPREL BI-FORT, na-agbaso iwu dọkịta mgbe niile. Ọ bụrụ n’inwe obi abụọ banyere izi ezi nke ọgwụ a, ị kwesịrị ịkpọtụrụ dọkịta gị ma ọ bụ onye na-ere ọgwụ. Ọgwụ ị na -emekarị bụ otu mbadamba kwa ụbọchị: Ọ ka mma iwere mbadamba ihe n'ụtụtụ, tupu nri. Were iko mmiri were tebụl ahụ mee ihe.

Mmetụta akụkụ

Dịka ọgwụ ọ bụla ọzọ, NOLIPREL BI-FORTE, ọ bụ ezie na ọ bụghị na ndị ọrịa niile, nwere ike ibute nsonaazụ.

Kwụsị ị thisụ ọgwụ a ozugbo ma kpọtụrụ dọkịta gị ma ọ bụrụ na ị nwere otu n'ime ọnọdụ ndị a:

ihu gị, egbugbere ọnụ gị, ọnụ gị, ire gị ma ọ bụ akpịrị gị zara aza, ị nwere ume iku ume, ị na-ama oke ure ma ọ bụ na-atụfu mmụọ, ị nwere ọnya obi na-adịghị adị ma ọ bụ nke na-adịghị ala ala.

Nsonaazụ nwere ike ịgụnye (n'ibelata oge ole a na-elele):

Ahụkarị (ihe na-erughị 1 n’ime 10, mana ihe karịrị otu onye n’ime 100 ndị ọrịa): isi ọwụwa, ịmịchaa ihe, vertigo, mkpịsị aka na ịma jijiji, ọhụhụ, tinnitus, isi mkpịsị ala n’ihi ọbara ọgbụgba dị ala, ụkwara, mkpụmkpụ ume, nsogbu ọgbụgba. , ọgbụgbọ, mgbu afọ, ọgba aghara nsogbu, ọnụ akọrọ, dyspepsia ma ọ bụ mgbaze siri ike, afọ ọsịsa, afọ ntachi), mmeghachi omume nfụkasị (dịka ọnya anụ ahụ, itching), olu mgbu, na-enwe ike ọgwụgwụ.

Ihe ojoo (erughi 1 n’ime 100, mana ihe kariri 1 n’ime ndị ọrịa 1000): mgbanwe ọnọdụ, nsogbu ịrahụ ụra, nrịanrịa, iku ume: yana iku ume), angioedema (akara dị ka isi ike ma ọ bụ ọsụsọ nke ihu na ire) , urticaria, purpura (ọnya na-acha ọbara ọbara na akpụkpọ ahụ), nsogbu akụrụ, enweghi ike, ịsụsọ.

Ọ dị ụkọ (ihe na-erughị 1 n’ime ndị ọrịa 10,000): ọgba aghara, akwara obi (ọrịa obi na-adịghị ala ala, nkụchi obi), ọrịa oyibo eosinophilic (ụdị oyi ịba), rhinitis (mkpọchi imi ma ọ bụ imi imerụ), mmeghachi omume anụ ahụ dị ukwuu dịka multiforme erythema. Ọ bụrụ na ị na-arịa ụdi systemic lupus erythematosus (ụdị ọrịa collagen-vaskụla ụkwara), mgbe ahụ ị ga-enwe ike ịda mba. Enwere mkpesa banyere nsogbu ndị metụtara mmeghachi omume foto (mgbanwe n'ọdịdị, ọdịdị nke anụ ahụ) mgbe ekpughechara anyanwụ ma ọ bụ ụzarị UVA.

Ọgba aghara na ọbara, akụrụ, umeji, akwara ma ọ bụ mgbanwe na plọg lab (nyocha ọbara) nwere ike ime. Dọkịta gị nwere ike inye gị nnwale ọbara iji lelee ọnọdụ gị.

Bụrụ na nke ọrịa imeju (ọrịa imeju), mmalite nke hepatic encephalopathy (ọrịa ụbụrụ na-emebi emebi) ga-ekwe omume.

Ọ bụrụ na nsonaazụ ya dị njọ ma ọ bụ ọ bụrụ na ị chọpụta na-enweghị mmetụta edepụtara na mpempe akwụkwọ a, gwa dọkịta gị ma ọ bụ onye na-ere ọgwụ.

Mmekọrịta na ọgwụ ndị ọzọ

Gwa dọkịta gị ma ọ bụ onye na-ere ọgwụ mgbe niile ọgwụ ị na-a orụ ma ọ bụ ị haveụrụ n’oge na-adịbeghị anya, ọbụlagodi ma ọ bụrụ na ọgwụ ndị a abụghị.

Zere iji ọgwụ NOLIPREL BI-FORTE nwee ọgwụ ndị a:

- lithium (nke a na - emeso ịda mbà n'obi),

- potassium-sparing diuretics (spironolactone, triamteren), nnu nnu.

Ojiji nke ọgwụ ndị ọzọ nwere ike imetụta ọgwụgwọ nke NOLIPREL B-FORT. Gbalịa ịkọrọ dọkịta gị ma ọ bụrụ na ị na-a drugsụ ọgwụ ndị na-esonụ, ebe ị ga-akpachapụ anya mgbe ị na-a themụ ha:

- ọgwụ eji eme ọgwụgwọ nke ọbara mgbali elu,

- procainamide (maka ọgwụgwọ ọrịa obi ara),

- allopurinol (maka ọgwụgwọ gout),

- terfenadine ma ọ bụ astemizole (antihistamines maka ịgwọ ọrịa hay ma ọ bụ nfụkasị ahụ),

- corticosteroids, nke a na-eji agwọ ọrịa ọnọdụ dị iche iche, gụnyere ụkwara ume ọkụ na ọrịa ogbu na nkwonkwo,

- ọgwụ mgbochi immunosuppressive nke a na-eji agwọ ọrịa nsogbu autoimmune ma ọ bụ mgbe arụchara ntụgharị iji gbochie iju (wdg.

- ọgwụ edepụtara maka ọgwụgwọ kansa,

- erythromycin intravenously (ọgwụ nje)

- halofantrine (a na-eji ya agwọ ụdị ọrịa ịba ụfọdụ),

- pentamidine (ejiri ya na-agwọ oyi baa).

- vincamine (ejiri ya maka ọgwụgwọ symptomatic nke nsogbu ọgụgụ isi na ndị ọrịa agadi, gụnyere enweghị ncheta).

- bepridil (a na - eji angina pectoris),

- sultoprid (maka ọgwụgwọ nke psychosis),

- ọgwụ edepụtara maka ọgwụgwọ nke ọrịa arrhythmias (dịka ọmụmaatụ quinidine, hydroquinidine, obedipyramide, amiodarone, sotalol).

- digoxin ma ọ bụ ọrịa glycosides ndị ọzọ (maka ịgwọ ọrịa obi),

- baclofen (maka ọgwụgwọ nke akwara ike, nke na - apụta na ọrịa ụfọdụ, dịka ọmụmaatụ, yana ọrịa sclerosis),

- ọgwụ shuga dị ka insulin ma ọ bụ metformin,

- kalsal, gụnyere nri mgbakwunye

- nri ndị na - akpali akpali (dịka senna),

- ọgwụ mgbochi mkpali na - abụghị steroidal (dịka ọmụmaatụ ibuprofen) ma ọ bụ oke nke salicylates (dịka eg aspirin),

- amphotericin B intravenously (maka ọgwụgwọ nke ọrịa fungal dị njọ),

- ọgwụ maka ịgwọ ọrịa uche, dịka ịda mba, ụjọ, schizophrenia, wdg (dịka ọmụmaatụ, tricyclic antidepressants, antipsychotics),

- tetracosactide (maka ọgwụgwọ nke ọrịa Crohn).

Njirimara ngwa

Drikwọ ụgbọ ala na igwe na-achịkwa, ..

NOLIPREL BI-FORTE anaghị emetụta akpachapụ anya, mana na ụfọdụ ndị ọrịa, n'ihi ọbara mgbali dị ala, mmeghachi omume dị iche iche nwere ike ịpụta, dịka ọmụmaatụ, dizzness ma ọ bụ adịghị ike. N’ihi nke a, enwere ike imebi ụgbọala ma ọ bụ usoro ndị ọzọ.

NOLIPREL BI-FORTE nwere lactose (bariki n’arụ). Ọ bụrụ na dọkịta gwara gị na ị naghị anabata ụfọdụ ụdị shuga, jụọ dọkịta gị tupu ị takingụ ọgwụ a.

Ọnọdụ nchekwa

Na-apụ n'anya na-ahụkarị ụmụaka.

Mechie akpa ike iji gbochie mmiri ịbanye.

Ekwesịrị ịchekwa ọgwụ a na okpomọkụ agaghị agafe 30 Celsius.

Etinyekwala ọgwụ ahụ n’ime mmiri mmiri ma ọ bụ nsị mmiri. Jụọ onye na-ere ọgwụ gị ka esi wepu ọgwụ ndị a kwụsịrị. Ebumnuche ndị a bụ ichebe gburugburu ebe obibi.

Mlọ ọgwụ

Noliprel A Bi-Forte bụ onye na - ejikọta ọnụ nke gụnyere angiotensin na - agbanwe enzyme inhibitor (ACE) na sulfonamide diuretic. Ihe ogwu a bu ihe eji eme ka aru mmadu mejuputa ihe ndi ozo na aru oru ya. Ngwongwo ihe ogwugwu ahu bu nke anakpo ha n’ihi ngbakwunye mmata ha.

Perindopril bụ ihe mgbochi ACE, nke a na-akpọ. kininase II - exopeptidase tinyere na ntụgharị nke angiotensin nke m ka ọ bụrụ ihe oriri nke vasoconstrictor angiotensin nke II, yana mmebi nke bradykinin, nke nwere mmetụta vasodilating, iji mepụta heptapeptide na-adịghị arụ ọrụ. Ihe a na - ebelata mmepụta nke aldosterone, na plasma ọbara ọ na - eme ka mmụba nke ọrụ renin site na ụkpụrụ nke nzaghachi na - adịghị mma, na iji ogologo oge ọ na - emebi usoro mkpokọta akwara nke oke (OPSS), nke a na - ejikọ karịa na mmetụta na arịa nke akwara na akụrụ. Ihe omume ndị a anaghị eweli ihe egwu nke etolite tachycardia ma anaghị ebute njigide mmiri na sodium.

Inye aka na mbenata mbido na nbudata, perindopril na - eme ka aka ya sie ike ma na - akwado akwara obi. N'ime ndị ọrịa nwere ọrịa obi obi na-adịghị ala ala (CHF), n'ihi ihe ọ rụpụtara (dịka ihe ngosipụta hemodynamic), imeju nrụgide n'akụkụ aka nri yana akụkụ aka nke obi na-ebelata, olu obi na-ebelata, npụtapụta obi na njịga obi, na-abawanye, na uru akwara ọbara na-abawanye.

Indapamide bụ sulfonamide otu ma gosipụta ihe ndị dị na ọgwụ ọgwụ yiri nke thiazide diuretics. Site na igbochi sodium reabsorption na mpaghara cortical nke Henle loop, ihe ahụ na-eme ka ekpughepụ dị ukwuu site na akụrụ nke sodium na chlorine ion, yana ruo ntakịrị - magnesium na ion potassium, nke na-eduga n'ịba ụba mmamịrị yana mbelata ọbara mgbali.

Noliprel A Bi-Forte na-egosipụta mmetụta pụrụ ịdabere na hypotensive na diastolic na mgbali ọbara systolic, ma na-eguzo ọtọ ma na-edina. A na-ahụ mmetụta antihypertensive nke ọgwụ ahụ ruo awa 24. Ihe na-erughị otu ọnwa mgbe mmalite nke usoro ahụ, a na-enweta mmetụta ọgwụgwọ kwụsiri ike, ebe a na-anaghị ahụ ihe omume tachyphylaxis. Emecha ọgwụgwọ anaghị eduga mwepu. Onye na-ahụ maka ọgwụ mgbochi na - enyere aka belata ọkwa nke hypertrophy nke aka ekpe (GTL), melite ike nke akwara, belata OPSS, anaghị egbochi mgbanwe nke lipids - triglycerides, cholesterol zuru oke, cholesterol, ala na njupụta lipoproteins (LDL na HDL).

E gosipụtara mmetụta ojiji nke perindopril na ebepamide na GTL ma e jiri ya tụnyere enalapril. N'ime ndị ọrịa nwere ọbara mgbali elu na GTL, onye were perindopril erbumin na 2 mg (nke kwekọrọ na perindopril arginine na ọnụọgụ 2,5 mg) + ebepamide na dose 0.625 mg / enalapril na dose nke 10 mg otu ugboro n'ụbọchị, mgbe ọ mụbara ọgwụ perindopril erbumin ruo 8 mg (nke kwekọrọ na perindopril arginine na ọnụọgụ 10 mg) + ebepamide - ruo 2.5 mg / enalapril - ruo 40 mg, yana otu nchịkwa otu na perindopril / ebepamide otu ma e jiri ya tụnyere enalapril otu, a na-achọpụta mbelata dị ukwuu na nchịkọta ventricular uka index ahụ. LVMI). Achọpụtara mmetụta kachasị dị na LVMI mgbe ị na-eji perindopril erbumin 8 mg + ebepamide 2.5 mg.

Achọpụtara mmetụta antihypertensive siri ike n'oge ọgwụgwọ jikọtara ya na perindopril na ebepamide ma e jiri ya tụnyere enalapril.

Achọpụtara ịdị irè nke perindopril na ọgwụgwọ nke ọbara ọgbụgba akwara nke nrụgide ọ bụla, ma yana ọrụ plasma renin dị ala na nke nkịtị. Mmetụta antihypertensive kachasị nke ihe a na-ahụta awa 4-6 ka nchịkwa ọnụ wee dịgide karịa awa 24. Mgbe oge a gasị, ọkwa dị elu (ihe dị ka 80%) nke ihe nchekwa ACE residual ka amaara.

Ojiji nke thiazide diuretics na-eduga na mmụba n'ịdị njọ nke mmetụta antihypertensive. Ọzọkwa, njikọta nke ihe ACE na mgbochi thiazide diuretic na-enyere aka belata ihe ize ndụ nke hypokalemia na iji ọnya ọnya.

Nchikota nke ihe mgbochi ACE na mgbochi antiotistin II nke mgbochi (ARA II) nke usoro renin-angiotensin-aldosterone (RAAS) ka akwadoro maka ndị ọrịa nwere ọrịa nephropathy. Emere nkwubi okwu a n'oge ikpe nke ndị ọrịa nwere ọrịa obi na ọrịa ọria ụbụrụ, ma ọ bụ ụdị ọrịa shuga nke 2 nwere nkwenye ọnya ahụ, yana ndị ọrịa nwere ụdị shuga 2. ụdị na ọrịa mamịrị nephropathy. Dabere na nsonaazụ nke ọmụmụ na ndị ọrịa na-anata usoro ọgwụgwọ a, enweghị mmetụta dị mma na mmepe nke akụrụngwa yana / ma ọ bụ ọrịa obi na ọnụego ndị nwụrụ. Ọzọkwa, iyi egwu nke hyperkalemia, hypotension art na / ma ọ bụ nnukwu gbasara akụrụ na nke a kawanyere njọ ma e jiri ya tụnyere otu ndị ọrịa na-anata monotherapy.

A na-ahụkarị ọgwụ antihypertensive nke ebepamide n'oge ọgwụgwọ a na usoro ọgwụgwọ na-enye ntakịrị mmetụta diuretic. Ngwongwo nke ihe ahu no na aru oru bu n'ihi mmụba nke akwara dị ukwuu na mbelata OPSS. Indapamide loro GTL, anaghị emetụta akpịrị ọbara (LDL, HDL, cholesterol, triglycerides) na ngụkọta carbohydrate ọbụlagodi ọnụnọ shuga.

Perindopril

Mgbe a na -ekwu ya n'ọnụ, perindopril na-abanye ngwa ngwa. Oke kachasị nke ihe ahụ (C_max) n'ime plasma ọbara a na-ahụ 1 awa mgbe nchịkwa gasịrị. Amaghị ọgwụ a. Nkera-ndu (T_1/2) bụ elekere 1. Ihe dị ka pacenti iri abụọ na asaa (27%) nke ọgwụ perindopril dị na ọbara n'ọdịdị nke metabolite nọ n'ọrụ, perindoprilat. Na usoro nke biotransformation nke ihe na-arụ ọrụ, na mgbakwunye na perindoprilat, a na-ehibe metabolites 5 ọzọ na-adịghị arụ ọrụ. Mgbe nchịkwa ọnụ gachara na plasma ọbara_max a na-enweta perindoprilat mgbe awa 3-4 gachara, nri iri nri na-ebelata ntụgharị nke perindopril gaa perindoprilat, si otú a na-emetụta bioavailability nke ọgwụ ahụ.

E guzobere usoro kwụ ọtọ nke larịị nke perindopril na plasma n'ihe ọ doseụrụ. Olu nkesa nkesa (V_d) perindoprilat na-enweghị ego nwere ike ịbụ ihe dịka 0.2 l / n'arọ. Na protein plasma, ọkachasị enwere ACE, perindoprilat (dabere na ịta) na-ejikọ ihe dị ka 20%.

Metabolite nọ n'ọrụ na-ewepụta akụrụ site n'ahụ ya, T_1/2 iberibe ezughi oke bụ ihe dịka awa iri na asaa, a na-erite ọkwa ịha nhata n'ime ụbọchị anọ.

Ọnụnọ obi na akụrụ dara, yana ndị ọrịa agadi, excretion nke perindoprilat na-eji nwayọ nwayọ. Nchọpụta nyocha nke ihe ahụ bụ 70 ml / min.

A na-enweta ngwa ngwa ahụ ngwa ngwa ma zuo oke na eriri afọ (GIT). Otu elekere gachara nchịkwa ọnụ, ana - enweta C_max ebepamide n'ime plasma ọbara. Site n'iji ya eme ihe ugboro ugboro, enweghi nchịkọta nke ihe ahụ. Nkwukọrịta na protein ndị dị na plasma bụ 79%, T_1/2 dịgasị iche n’agbata awa iri na anọ ruo n’awa iri abụọ na anọ (nkezi nke awa 18).

Indapamide na-abụkarị site akụrụ (ihe dịka 70% nke dose ahụ) yana n'ụdị metabolites na-adịghị arụ ọrụ site na eriri afọ (ihe dịka 22%).

Usoro ọgwụ pharmacokinetic dị na ndị ọrịa nwere ọdịda akụrụghị agbanwe.

Ntụziaka pụrụ iche

N'ime oge ọgwụgwọ, ekwesịrị ịtụle akara ngosipụta nke akpịrị nkụ na mbelata ọkwa plasma nke electrolytes, gụnyere afọ ọsịsa na / ma ọ bụ ọgbụgbọ, ebe ọ bụ na n'ọnọdụ nke hyponatremia na mbụ n'ihe ize ndụ nke nnukwu mmepe nke hypotension na-abawanye. N'ọnọdụ ndị dị otú a, achọrọ nlebara anya gbasara mkpokọta electrolytes na plasma ọbara.

Ọ bụrụ na achọpụta hypotension siri ike, ana-edenye nchịkwa nke 0.9% sodium chloride solution.

Ọbara mgbatị ọbara abụghị ihe mgbochi maka ọgwụgwọ ọzọ na Noliprel A Bi-Fort. Site n'ịgbaso usoro ịbawanye ọbara na bcc, ị nwere ike ịmaliteghachi iji ọgwụ ahụ na obere doses, ma ọ bụ jiri naanị otu n'ime ihe ndị na-arụ ọrụ.

N'aka usoro ọgwụgwọ, e dere ihe banyere ajọ ọrịa na-efe efe, mgbe ụfọdụ na-eguzogide ọgwụ ọgwụ ike. Mgbe ị na-eji perindopril na ndị ọrịa dị otú a, ọ dị mkpa iji nlele nyochaa oge nke leukocytes n'ọbara. Ndị ọrịa kwesịrị ịgwa dọkịta ha banyere ihe mgbaàmà ọ bụla nke ọrịa na-efe efe (gụnyere ahụ ọkụ na ọnya ọnya).

N'oge ọgwụgwọ nke Noliprel A Bi-Forte, edepụtara ọtụtụ okwu banyere mmepe nke angioedema nke ire, egbugbere ọnụ, mkpịsị olu na / ma ọ bụ nkọlọ, ihu na aka ya. Ọrịa ndị a nwere ike ịda n'oge ọ bụla n'oge ọgwụgwọ. Mgbe ihe mgbaàmà nke ụbụrụ angioneurotic pụtara, ekwesịrị ịkwụsị ọgwụ ahụ ozugbo ma kwadosie ọnọdụ onye ọrịa ahụ ruo mgbe ewepụrụ ihe ịrịba ama nke ọnya a kpamkpam. Ọ bụrụ na ọzịza agbasaala na ihu na egbugbere ọnụ, mgbe ahụ n'ọtụtụ oge mgbaàmà ahụ na-apụ n'onwe ha, ọ bụ ezie na ọ dị mkpa, a nwekwara ike ịkọ ọgwụ antihistamines. Ọkpụkpụ Angioneurotic, tinyere ụrọ laryngeal, nwere ike ibute ọnwụ. Okpoko nke olu ana - ekwu okwu, ire ma obu ogwurugwu na –eme ka ohere nke mgbochi ikuku gbue. Site na mmepe nke mgbaàmà ndị a, a na-atụ aro ka itinye epinephrine ozugbo (adrenaline) na mbuze nke 1: 1000 (0.3-0.5 ml) ma ọ bụ mee ihe iji hụ na ịgbachapụ okporo ụzọ.

Enwere akụkọ banyere ihe egwu dị elu nke ọrịa angioedema na ndị ọrịa agbụrụ Negroid.

N'ọnọdụ ndị na-adịghị ahụkebe, n'oge ọgwụgwọ nke ndị na - egbochi ACE, a hụrụ mmepe nke angioedema nke eriri afọ, tinyere mgbu n'ime afọ (ya na ma ọ bụ na ọ nweghị ihe ọgbụgbọ / ọgbụgbọ), mgbe ụfọdụ yana ịta ọkwa C1 esterase na enweghị ọdịdị nke ihu ihu mbụ. Achọpụtara nchoputa nke mmeghachi omume ọjọọ a site na nyocha nke tomography (CT) nke oghere nwa, ultrasound (ultrasound) ma ọ bụ n'oge ịwa ahụ. Ọrịa ọgbụgba na-akwụsị mgbe ndọrọpụrụ ndị na - egbochi ACE.

N'ime ndị ọrịa nwere ihe nfụkasị ahụ, mgbe ha na-ewere enweghị nchekwube, ekwesịrị iji akpachapụ anya ACE na-akpachapụ anya. Ndị ọrịa na-anata ọgwụ mgbochi yana nkwadebe nwere nje ahụhụ hymenopteran (gụnyere a beesụ na beps) kwesịrị izere iji ndị na-egbochi ACE, ebe ọ bụ na nke a na-abawanye ihe ize ndụ nke ịmaliteghachi mmeghachi omume ogologo oge na ihe na-eyi ndụ egwu. Agbanyeghị, enwere ike ịhapụ mmerụ ahụ ndị a site na kagbuo ndị na - egbochi ACE ma ọ dịkarịa ala awa iri abụọ tupu usoro desensitization.

Na ọnụnọ nke ọbara mgbali elu na akwara obi n'oge ọrịa, ndị ọrịa ekwesịghị ịkwụsị iji ọgwụ mgbochi beta.

Perindopril, dịka ndị ọzọ na-egbochi ACE, na-egosi mmetụta antihypertensive na-adịghị ike na ndị ọrịa nke agbụrụ Negroid ma e jiri ya tụnyere ndị nnọchi nke agbụrụ ndị ọzọ. E kwenyere na ọdịiche a bụ n'ihi ọrụ ana-ekwukarị ugboro ugboro na ndị ọrịa nke agbụrụ ha nwere ọbara mgbali elu.

Na agbanyeghi usoro ọgwụgwọ na thiazide diuretics, enweela ọnọdụ nke mmeghachi omume foto, mmepe nke chọrọ ọgwụ a ga-akwụsị. Ọ bụrụ na ị ga-aga n’ihu n’ịgwọ ọrịa akwara, a na-atụ aro ichebe akpụkpọ ahụ ka ọ ghara ịchapụta ìhè anyanwụ na ụzarị ultraviolet.

Indapamide nwere ike ịkpalite mmeghachi omume dị mma na ndị na-eme egwuregwu n'oge nchịkwa doping.

Mmetụta ikike ịkwọ ụgbọala na usoro dị mgbagwoju anya

Ihe ndị na - arụ ọrụ nke Noliprel A Bi-Forte anaghị eduga n'ọgba aghara na mmeghachi omume psychomotor. Mana ekwesịrị iburu n'uche na n'ụfọdụ ndị ọrịa, mmeghachi omume onwe onye nwere ike ịmalite na nzaghachi mbelata ọbara mgbali, karịsịa na mmalite nke ọgwụgwọ ma ọ bụ iji n'otu oge na ọgwụ ndị ọzọ antihypertensive. N'okwu a, ike ịkwọ ụgbọala ma ọ bụ ịrụ ọrụ na igwe ndị ọzọ nwere ike ibute nsogbu nwere ike ịnwe mmachi.

Ime na lactation

Womenmụ nwanyị dị ime na ụmụ nwanyị na-eme atụmatụ ịtụrụ ime ekwesịghị iwe Noliprel A Bi-Forte. Emebeghi ihe omumu ihe omuma banyere ogwu na ndi ACE na ndi nwanyi ime. Enwere data na nsonaazụ ọgwụ ahụ n'oge ọnwa atọ nke ịtụrụ ime na-egosi na enweghị nkwarụ mmepe ya na ọgwụ metụtara fetotoxicity. Na agbanyeghị nke a, mmụba nke ihe egwu nsogbu nsogbu ịmụ nwa ebu n'afọ enweghị ike ikpochapu ya mgbe ị na - ewere ndị na - egbochi ACE.

Ọ bụrụ na ime amalitela n'oge ọgwụgwọ na ọgwụ ahụ, ọ dị mkpa ịkwụsị ozugbo iji Noliprel A Bi-Forte ma depụta usoro ọgwụgwọ ọgwụ mgbochi ọzọ na ọgwụ akwadoro iji n'oge afọ ime. N’ime ogwe aka nke II - III, na iwere ogologo oge nye ndị na-egbochi ACE na nwa ebu n’afọ, ihe ọghọm nke nsogbu etolite, dịka oligohydramnion, ọrụ ezughi oke, yana igbu oge n’arụ ọkpụkpụ okpokoro isi. Nwa amụrụ ọhụrụ nwere ike ịnwe ike hypotension, ọrịa gbasara akụrụ, hyperkalemia.

Ọ bụrụ na nwanyị nwetara ọgwụgwọ na ndị na - egbochi ACE na oge nke II - III nke afọ ime, a ga-eme nyocha nke nwa ebu n’afọ iji chọpụta ọrụ nke akụrụ na ọnọdụ nke okpokoro isi. Mụ amụrụ ọhụrụ ndị nne ha theseụrụ ọgwụ ndị a n'oge afọ ime chọrọ nlekọta nlekọta ahụike maka nchọpụta oge na nchọpụta nke hypotension akwara ike.

N'ime oge nke atọ nke afọ ime, ọgwụgwọ ogologo oge na thiazide diuretics nwere ike ibute hypovolemia nne na mbelata ọbara nke uteroplacental, na-ebute isọkpụ fetoplacental na azụ nwa ebu n’afọ. Mgbe a na-emeso ndị ọrịa diuretics, obere oge tupu a mụọ ha, n'ọnọdụ ụfọdụ, ụmụ amụrụ ọhụrụ nwere thrombocytopenia na hypoglycemia.

Iji Noliprel A Bi-Forte n'oge inye ara na-egbochi imebi. Amabeghị ma perindopril banye na mmiri ara ara, mana e guzobewo na ebepamide dị na mmiri ara nke mmadụ ma nwee ike bute nwa amụrụ ọhụrụ na mmepe nke hypokalemia, nuklia jaundice na hypersensitivity na usoro sulfonamide. Takingụ ọgwụ osisi thiazide nwere ike kpasu iwe iwelata mmiri ara ehi ma ọ bụ belata obere mmiri ara.

Na arụ ọrụ ezumike ọrụ

Ndị ọrịa nwere CC ≥60 ml / min n'oge ọgwụgwọ chọrọ ka a na-enyocha ya mgbe niile gbasara ọkwa nke potassium na creatinine na plasma ọbara.

Na ọnụnọ nke obere gbasara akụrụ na-ada ada (CC erughi 60 ml / min), Noliprel A Bi-Forte na-contraindicated. N'ebe ụfọdụ ndị ọrịa nwere ọbara mgbali elu na-enweghị ihe mgbaàmà doro anya nke ọrụ na-akpata nsogbu ezumike, ihe nyocha ụlọ nyocha nwere ike igosi ihe ịrịba ama nke ọdịda akwara afọ. N'ụdị ndị a, a ga-akwụsị ịgwọ ọrịa ọgwụ. Inwere ike ịmaliteghachi ọgwụgwọ na obere usoro nke ngwakọta nke ihe ndị na - arụ ọrụ, ma ọ bụ iji naanị otu ọgwụ. N'ime ndị ọrịa nọ n'otu ndị a dị ize ndụ, ekwesịrị ileba anya n'ọtụtụ selin na potassium ka izu abụọ gachara ịmalite Noliprel A Be-Forte ma mesịa kwa ọnwa abụọ. Maka akụkụ kachasị, ọdịda akụrụngwa na-eme na ndị ọrịa nwere nsogbu akụrụ mbụ (gụnyere akụrụ akwara akwara) ma ọ bụ nnukwu nkụchi obi.

Site na ịrụ ọrụ ọrụ imeju

Na ọnụnọ nke ọrịa akwara dara ada, a na-egbochi ọgwụ Noliprel A Bi-Forte. Ndị ọrịa nwere oke ịba ọcha ọria ekwesịghị ịhazigharị dose.

N'ụfọdụ, n'oge eji ACE inhibitors, a hụrụ ngosipụta nke cholestatic jaundice. Na-emegide nzụlite nke mmetụta a na - esi n'akụkụ ọwụwa, mmepe nke negirossi imeju zuru oke ga - ekwe omume, mgbe ụfọdụ yana nsonaazụ na - egbu egbu. Usoro maka mmepe nke nsogbu a edoghị anya. Ọ bụrụ na n’oge ị Nụ ọgwụ Noliprel A na-enwe Bi-Forte, ma ọ bụ na - emeju enzyme nke imeju na-abawanye, a ga-akwụsị ịgwọ ọrịa ma gwaa dọkịta.

Takingụ mkpụrụ osisi thiazide / thiazide dịka ọrịa imeju dị ugbu a nwere ike ibute mmepe nke encephalopathy hepatic. N'okwu a, ọ dị mkpa ịkwụsị ọgwụgwọ ozugbo na Noliprel A Bi-Fort.

Jiri na agadi

Tupu a gwọọ ya, ndị ọrịa merela agadi kwesịrị inyocha akụrụngwa na-arụ ọrụ nke akụrụ na ntụpọ plasma nke potassium na ọbara. N'ime ụdị ndị ọrịa, ekwesịrị ikpebi ọkwa plasma creatinine na-eburu afọ, ogo ahụ na okike. Na nmalite usoro ọgwụgwọ maka ndị agadi, a na-etinye dose nke perindopril dabere na ọkwa nke mbelata ọbara mgbali, karịsịa na mbelata bcc na ọnwụ electrolytes. Usoro ndị a na - enyere aka izere ịdalata ọbara mgbali elu.

Agadi ndị ọrịa nwere ọrụ ezumike nkịtị Noliprel A Bi-Forte ka akwadoro ị were mbadamba mbadamba 1 n'otu oge kwa ụbọchị.

Mkparịta ụka ọgwụ ọjọọ

Ngwakọta ndị a tụrụ aro ya na Noliprel A Bi-Forte, ma ọ bụ ihe ndị ọzọ na-arụ ọrụ na nkwadebe:

• ịkwado lithium: ihe ọghọm nke mmụba mgbanwe nke lithium na plasma ọbara na nsonaazụ nsenaazụ ya mgbe ị na-ewere ndị na-egbochi ACE na-abawanye, ojiji ndị ọzọ nke thiazide diuretics nwere ike ibute mmụba na ọkwa nke lithium ma nwekwuo ihe egwu nke nsí, ma ọ bụrụ na njikọ dị otú ahụ dị mkpa, ekwesịrị ilebara ọkwa ahụ anya mgbe niile. plasma lithium,
• estramustine: egwu nke mmụba na ugboro ugboro nke mmetụta na-adịghị mma, gụnyere angioedema, na-abawanye mgbe ejiri ya na perindopril,
• Nhazi potassium, mkpụrụ ọgwụ na-enye ume ọgwụ (spironolactone, amiloride, triamteren, eplerenone), nwere ihe ndị na-enye potassium maka nnu a na-eri: ọkwa potassium na-adịkarị n’ogwe ala, hyperkalemia adịkarịghị ike ịmalite - mgbe ejikọtara ya na ndị na-egbochi ACE, ọgwụ ndị a niile na-ewere ọgwụ ahụ n'otu oge. nwere ike ibute mmụba dị ukwuu na potassium serum ruo ọnwụ, na hypokalemia enwetara, a ga-elekọtarịrị nlebara anya na nlele anya mgbe niile g plasma ịta potassium na ECG parameters.

Mmeghachi omume mmekọrịta enwere ike ịchọrọ nlebara anya pụrụ iche na ịkpachara anya maka ojiji Noliprel A Bi-Fort ma ọ bụ ihe eji arụ ọrụ ya na ọgwụ / ọgwụ ndị a:

• baclofen: mmetụta antihypertensive na-abawanye, ọbara mgbali elu na ọrụ akụrụ kwesịrị ịchịkwa, ọ bụrụ na ọ dị mkpa, ekwesịrị ịme mmezi nke ọgwụ antihypertensive,
• NSAIDs (gụnyere acetylsalicylic acid na doses karịrị 3,000 mg kwa ụbọchị, NSAIDs na-abụghị nhọrọ NSAIDs na COX-2 inhibitors): mmetụta antihypertensive nwere ike belata mgbe ejikọtara ya na ndị na-egbochi ACE, ihe ize ndụ nke ọrụ ịkpọkasị arụ ọrụ, gụnyere ọdịdị nke ọdịda akwara nnukwu, na-abawanye, na mmụba na ọkwa potassium n'ụba, tumadi na ndị ọrịa nwere nsogbu izizi nsogbu gbasara akụrụ, ndị ọrịa kwesịrị iweghachi nguzo mmiri na-enyocha ma na-enyocha mgbe niile na mmalite nke ọgwụgwọ nkwonkwo na n'oge ọrụ ya ochek,
• ndị na-arịa hypoglycemic nke sitere na sulfonylureas: mmetụta hypoglycemic nke ọgwụ ndị a na insulin na ndị ọrịa nwere ọrịa mellitus na-abawanye site n'iji ndị na-egbochi ACE, hypoglycemia dị ụkọ, n'ihi mmụba nke nnabata glucose na mbelata nke insulin, a chọrọ nlebara anya nke ọkwa glucose plasma mgbe niile. n'ọnwa mbu nke ngwakọta a,
• antiarrhythmics nke klas IA (quinidine, disopyramide, gidrohinidin) na klas III (bretylium tosylate, dofetilide, amiodarone, ibutilide), sotalol, benzamides (sultopride, amisulpride, tiapride, sulpiride), neuroleptics (levomepromazine, chlorpromazine, tsiamemazin, trifluoperazine, thioridazine) , butyrophenones (droperidol, haloperidol), pimozide, difemanila methylsulfate, sparfloxacin, bepridil, halofantrine, cisapride, moxifloxacin, erythromycin (w / w), pentamidine, mizolastine, vincamine (w / w), terfenadine, astemizole, methadone (mmadụ ike nke ibido a ụdị pirouette): ihe egwu nke hypokalemia na iji ebepamide na-akawanye njọ, na-achịkwa etiti oge QT, a chọrọ plasma potassium, ma ọ bụrụ na ọ dị mkpa, mgbazi nke hypokalemia,
• gluco- na mineralocorticoids (na-enwe nsonaazụ sistem), amphotericin B (iv), tetracosactide, laxatives nke na-eme ka mgbali eriri afọ (ndị nnọchi anya nke nwere ike ịkpalite hypokalemia): n'ihi mmetụta mgbakwunye ahụ, mgbe ejikọtara ya na ebepamide, ihe ize ndụ nke hypokalemia na-abawanye, a na-achọ nchịkwa potassium. na plasma, ọ bụrụkwa na ọ dịkwa mkpa na mgbazi ya, ndị ọrịa na-anata obi glycosides chọrọ nlezianya nyocha, a na-atụ aro iji ọgwụ a thatụ arụ na-adịghị akpali iruyut peristalsis,
• cardiac glycosides: a na-eme ka mmetụta nke ọgwụ ndị a na hypokalemia dịkwuo mma, yabụ, mgbe ejikọtara ya na ebepamide, ekwesịrị ilebara ọdịnaya potassium na plasma na ECG anya, enwere ike idozi ọgwụgwọ.
• Mmekorita nke choro nlebara anya ya na Noliprel A Bi-Fort ma obu ihe ndi n’oru ime ya nwere ogwu / ihe ndi a:
• tetracosactide, corticosteroids: a na - ebelata mmetụta antihypertensive, n'ihi njigide mmiri na sodium ion n'ihi mmetụta nke corticosteroids,
• ọgwụ antipsychotic (antipsychotics), ọgwụ mgbochi tricyclic: mmetụta antihypertensive na-abawanye na ihe iyi egwu hypotension orthostatic ka njọ (mmetụta na-agbakwunye),
• ọgwụ ndị ọzọ na - egbochi mkpali, vasodilators: nwere ike ịbawanye mmetụta hypotensive,
• ARA II inhibitors, aliskiren: mgbe ị na-eji ọgwụ ndị a ACE inhibitor na-a theseụ ọgwụ a, omume nke mmetụta ndị na-adịghị mma, dịka hyperkalemia, hypotension, nrụrụ gbasara akụrụ ọrụ (gụnyere akwara gbasara akwara), na-abawanye ma e jiri ya na otu ọgwụ na-emetụta ya. na RAAS, maka mgbakwunye nke mgbochi abụọ nke RAAS site na ijikọ ọnụ nke ACE inhibitor na ARA II ma ọ bụ aliskiren akwadoghị, ma ọ bụrụ na ngwakọta a dị mkpa, na-ahụ maka nlekọta ahụike siri ike, yana ileba anya mgbe niile gbasara ịta potassium na plasma, ọrụ akụrụ na mgbali ọbara,
• thiazide na loop diuretics (na nnukwu usoro): hypovolemia nwere ike ịmalite, mgbe agbakwunye ọgwụ ndị a na ọgwụgwọ perindopril, ihe ize ndụ nke hypotension arterial na-abawanye,
• ọgwụ cytostatic na immunosuppressive, allopurinol, corticosteroids (na-eji usoro), procainamide: ihe ize ndụ nke leukopenia na-abawanye mgbe na-ewere ndị na-egbochi ACE,
• nkwadebe maka ọgwụ ịwa ahụ ọhụụ: a na-enwekwu mmetụta antihypertensive mgbe ejikọtara ya na perindopril, a na-atụ aro ka ị kwụsị ị Nụ Noliprel A Bi-Forte ruo oge o kwere mee 24 awa tupu ịwa ahụ na-eji ọgwụ na-akụnwụ ahụ.
• gliptins (sitagliptin, saxagliptin, linagliptin, vildagliptin): ihe egwu nke angioedema na-abawanye mgbe ejikọtara ya na ndị na-egbochi ACE n'ihi mgbochi nke dipeptidyl peptidase-4 site na gliptin,
• ọrịa obi: a na-ebelata ọgwụ antihypertensive,
• Nkwadebe ọla edo (iv), gụnyere sodium aurothiomalate: site n'iji ọgwụ mgbochi ACE, mmeghachi omume nitrate nwere ike ịmalite, dị ka ọgbụgbọ, ọgbụgbọ, hypotension artpot, hyperemia nke akpụkpọ nke ihu.
• iodine nwere ihe ndi ozo di iche (dika otutu onunu): ihe isi ike nke imeputa oke gbasara akuru nke akpachapuru anya nke akpachapuru anya nke aru mgbe ị na-a drugsụ ọgwụ diuretic na-abawanye, tupu nchikota a, ọ dị mkpa iji weghachi mmiri mmiri,
• metformin: ihe ize ndụ nke lactic acidosis n'ihi ọdịda gbasara akụrụngwa akụrụngwa metụtara ị diụ diuretic (ọkachasị loopbacks) na-abawanye na ọkwa plasma creatinine nke 15 mg / l (135 μmol / l) na ụmụ nwoke na 12 mg / l n'ime ụmụ nwanyị ( 110 μmol / L) metformin ekwesịghị iji ya,
• calcium salts: hypercalcemia nwere ike itolite n'ihi mbelata akụrụ nke calcium ion,
• cyclosporine: na-abawanye itinye uche nke creatinine na plasma na enweghị mgbanwe na ọkwa ya, ọbụlagodi mmiri nkịtị na sodium ion.

Ihe atụ nke Noliprel A Bi-Fort bụ Noliprel A, Noliprel A forte, Ko-Perineva, Perindopril-Indapamide Richter, Co-Parnawel, Noliprel, Noliprel forte, Perindid, Perindapam, Perindopril PLUS Indapamide na ndị ọzọ.

Nyocha banyere Noliprel A Bi-Fort

Nyocha banyere Noliprel A Bi-Fort n'ọtụtụ oge dị mma. Ndị ọrịa rịbara ama na ọgwụ mgbochi jikọtara ọnụ n'ụzọ dị irè ma na-edozigharị ọbara mgbali elu, na-eme ka mgbidi nke arịa ọbara dịwanye nkọ ma na-enyere aka belata GTL. N'ime ndị ọrịa nwere ọrịa shuga, Noliprel A Bi-Forte anaghị emetụta glucose ọbara, n'adịghị ka ụfọdụ nke analogues ya. Ọtụtụ ndị dọkịta kwenyere na ọ dị mma maka ọgwụgwọ nke hypotension nwere mmezi usoro ọgwụgwọ ọzọ nwere ike.

Ọdịmma ọghọm nke ọgwụ ahụ gụnyere ọnụnọ nke nnukwu contraindications na nsonaazụ ndị ọ bụla enwere ike.